Andrew Gomperts
Founder at Hillhurst Biopharmaceuticals, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Edward Gomperts | M | - |
Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Hillhurst Biopharmaceuticals, Inc. is a private company that specializes in developing a gas in liquid advanced stability system called Hillhurst's proprietary GLASSTM platform. The company is based in San Diego, CA. This platform enables novel uses of therapeutic gases that were previously limited by inhaled delivery. The company has developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson's disease, and acute pain. The company was founded by Edward Gomperts. The CEO is Andrew Gomperts. | - |
Douglas Stockdale | M | - |
Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Hillhurst Biopharmaceuticals, Inc. is a private company that specializes in developing a gas in liquid advanced stability system called Hillhurst's proprietary GLASSTM platform. The company is based in San Diego, CA. This platform enables novel uses of therapeutic gases that were previously limited by inhaled delivery. The company has developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson's disease, and acute pain. The company was founded by Edward Gomperts. The CEO is Andrew Gomperts. | - |
Jeff Friedman | M | - |
Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Hillhurst Biopharmaceuticals, Inc. is a private company that specializes in developing a gas in liquid advanced stability system called Hillhurst's proprietary GLASSTM platform. The company is based in San Diego, CA. This platform enables novel uses of therapeutic gases that were previously limited by inhaled delivery. The company has developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson's disease, and acute pain. The company was founded by Edward Gomperts. The CEO is Andrew Gomperts. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 3 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Gomperts
- Personal Network